Study of the use of autologous platelet concentrate during pars-plana-vitrectomy for epiretinal gliosis and impending macular hole
- Conditions
- MedDRA 10064697
- Registration Number
- DRKS00027852
- Lead Sponsor
- GWT TUD GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 57
Inclusion Criteria
• Age = 18 years
• Patients with epiretinal gliosis and BCVA = 35 (according to ETDRS).
• Written informed consent to participate in the study
• Presence of an artificial intraocular lens
• Ability to donate autologous platelets
Exclusion Criteria
• Patients with own lens
• Treatment with intravitreal injections in the previous 3 months in the study eye
• Pathological changes of the anterior segment of the eye affecting BCVA (corneal opacities or similar)
• Acute inflammation in the study eye
• advanced glaucoma with optic atrophy and central visual field defects in the study eye
• wet form of age-related macular degeneration as well as advanced form of dry age-related macular degeneration (geographic atrophy)
• presence of pregnancy
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To investigate whether the intraoperative use of autologous platelet concentrate in patients with epiretinal gliosis and impending macular hole leads to better visual recovery than in patients without intraoperative platelet use.
- Secondary Outcome Measures
Name Time Method • Comparison of retinal recovery on OCT between patients with and without intraoperative use from autologous platelet concentrate.<br>• Comparison of visual recovery in patients with primary and secondary epiretinal gliosis.<br>• Comparison of visual recovery in patients with diabetes mellitus and without.<br>• Safety profile of intraoperative use of autologous platelet concentrate.